Paper Details

  1. Home
  2. Paper Details

ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.

Author: , AllardMartine, BadeschDavid B, DespainDarrin, DuftonChristopher, FarberHarrison W, FeldmanJeremy, FrostAdaani, KeoghAnne, MathierMichael A, McGoonMichael, OudizRonald J, RubinLewis J, ShapiroShelley

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ambrisentan, an endothelin receptor antagonist, was well tolerated and demonstrated benefits in patients with pulmonary arterial hypertension (PAH) of various etiologies, including those receiving other pulmonary hypertension therapies.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Ambrisentan is an oral, once daily, endothelin receptor antagonist approved for treatment of pulmonary arterial hypertension (PAH). Previous studies of ambrisentan were limited to patients with Group 1 PAH and often excluded patients receiving other pulmonary hypertension (PH) therapie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1755-5922.2011.00279.x

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Desert of Pulmonary Hypertension

Pulmonary hypertension, a condition that can feel like a relentless sandstorm in the lungs, requires specialized care. This study investigates the efficacy and safety of ambrisentan, an endothelin receptor antagonist, in treating pulmonary hypertension. The study examines the use of ambrisentan in a diverse population of patients with various etiologies of pulmonary hypertension, aiming to expand the understanding of this medication's potential benefits.

Ambresistan: A Promise of Relief

The study found that ambrisentan was well tolerated and provided benefits for patients with pulmonary arterial hypertension. This suggests that ambrisentan could be a valuable tool for managing the turbulent conditions of this disease.

Navigating the Desert with Ambresistan

This study offers hope for patients struggling with pulmonary hypertension. It suggests that ambrisentan could offer a smoother, more comfortable journey through the desert of this condition.

Dr.Camel's Conclusion

The desert of pulmonary hypertension can be a daunting one, but this study suggests that ambrisentan may be a promising oasis. It offers a potential avenue for managing the harsh conditions of this disease and improving the quality of life for those affected.

Date :
  1. Date Completed 2012-07-03
  2. Date Revised 2016-11-25
Further Info :

Pubmed ID

21884013

DOI: Digital Object Identifier

10.1111/j.1755-5922.2011.00279.x

Related Literature

Article Analysis
・Effective treatment of pulmonary hypertension
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.